Sirios Capital Management L P Purchases 4,310 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Sirios Capital Management L P grew its position in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 22.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 23,183 shares of the medical equipment provider's stock after acquiring an additional 4,310 shares during the period. Sirios Capital Management L P's holdings in Lantheus were worth $2,074,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of the business. Wilmington Savings Fund Society FSB acquired a new position in Lantheus during the 3rd quarter worth $25,000. Kestra Investment Management LLC bought a new position in shares of Lantheus in the 4th quarter valued at about $27,000. Summit Securities Group LLC acquired a new position in Lantheus in the fourth quarter valued at approximately $37,000. UMB Bank n.a. grew its holdings in Lantheus by 31.5% during the 4th quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider's stock worth $50,000 after acquiring an additional 134 shares during the period. Finally, World Investment Advisors LLC acquired a new position in shares of Lantheus in the 3rd quarter valued at $60,000. 99.06% of the stock is owned by institutional investors and hedge funds.

Lantheus Stock Performance

Shares of Lantheus stock traded up $0.29 during trading on Monday, reaching $102.06. 362,891 shares of the company's stock were exchanged, compared to its average volume of 953,006. Lantheus Holdings, Inc. has a 1-year low of $65.76 and a 1-year high of $126.89. The company has a market cap of $6.99 billion, a P/E ratio of 17.02 and a beta of 0.20. The firm's 50-day moving average price is $97.37 and its 200 day moving average price is $95.14.

Lantheus (NASDAQ:LNTH - Get Free Report) last announced its earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.57 by ($0.23). The company had revenue of $391.11 million for the quarter, compared to the consensus estimate of $376.61 million. Lantheus had a return on equity of 44.29% and a net margin of 28.57%. As a group, equities research analysts predict that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have weighed in on LNTH. JMP Securities reissued a "market outperform" rating and issued a $112.00 target price on shares of Lantheus in a research note on Tuesday, January 14th. B. Riley reduced their price objective on shares of Lantheus from $127.00 to $122.00 and set a "buy" rating on the stock in a research note on Friday, March 21st. Finally, Truist Financial upped their target price on shares of Lantheus from $120.00 to $127.00 and gave the company a "buy" rating in a research note on Thursday, February 27th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $129.43.

Insider Buying and Selling

In related news, CFO Robert J. Jr. Marshall sold 10,000 shares of the business's stock in a transaction on Monday, March 17th. The shares were sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the transaction, the chief financial officer now owns 113,860 shares in the company, valued at $11,445,207.20. The trade was a 8.07 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Mary Anne Heino sold 53,107 shares of the firm's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the completion of the sale, the director now owns 440,399 shares of the company's stock, valued at $41,551,645.65. The trade was a 10.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 63,109 shares of company stock valued at $6,016,046 over the last quarter. Insiders own 1.50% of the company's stock.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.